CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 52 enrolled
Drug / intervention
AMD3100 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00512252
NCT00512252Phase 2Completed
CompareCT.gov

A Phase I/II Study of AMD3100 With Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML

Washington University School of Medicine·interventional·Posted Aug 7, 2007·Updated Dec 12, 2016

In Brief

A Phase 2 clinical trial evaluating AMD3100, Mitoxantrone, and 2 other interventions for Leukemia, Myeloid, Acute. Completed, enrolled 52 participants across 1 site.

Detailed Summary

This study is a phase I/II study to determine the safety and efficacy of AMD3100 when combined with mitoxantrone, etoposide, and cytarabine in patients with relapsed or refractory AML. We hypothesize that disrupting the interaction between AML blasts and the marrow microenvironment with AMD3100 may enhance the cytotoxic effect of chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Myeloid, Acute
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 7, 2007
Enrollment StartJul 1, 2007
Primary CompletionJun 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 18.9 years ago

Interventions

AMD3100drug

Mitoxantronedrug

Etoposidedrug

Cytarabinedrug